Smith Group Asset Management’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Smith Group Asset Management’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-25,553	Closed	-$1.44M	–	457
2013 Q4	$1.44M	Buy	25,553 +6,751	+36%	+$379K	0.05%	167
2013 Q3	$1.15M	Sell	18,802 -1,948	-9%	-$132K	0.05%	172
2013 Q2	$1.21M	Buy	+20,750	New	+$1.28M	0.05%	177

Other funds holding OREX

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Smith Group Asset Management's OREX Position: Q1 2014 in Review

Smith Group Asset Management sold out of Orexigen Therapeutics, Inc. (OREX) in Q1 2014, closing a stake of 25,553 shares — an estimated $1.44M sold.

Smith Group Asset Management first reported a position in OREX in Q2 2013 and held it in 3 quarters. The position peaked at $1.44M in Q4 2013. 129 funds tracked by Wall St. Rank hold OREX as of Q1 2014.

Smith Group Asset Management reported no remaining Orexigen Therapeutics, Inc. position as of Q1 2014 after selling out during the quarter.
Smith Group Asset Management sold 25,553 Orexigen Therapeutics, Inc. shares in Q1 2014, an estimated $1.44M.
Smith Group Asset Management first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 3 quarters.
Smith Group Asset Management's Orexigen Therapeutics, Inc. position peaked at $1.44M in Q4 2013.
129 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q1 2014.

Based on Smith Group Asset Management's 13F filing for Q1 2014, filed 23 Apr 2014.